Mutations in LRRK2 are thus far the most frequent known cause of autosomal dominant and idiopathic Parkinson's disease (PD) with prevalent mutations being found within the GTPase (R1441C/G) and kinase (G2019S) domains. Previous in vitro studies have revealed that R1441C and G2019S mutations are associated with increased kinase activity. To better understand LRRK2-linked PD pathogenesis in vivo, we have generated transgenic C. elegans overexpressing human LRRK2 wild type, R1441C and G2019S in dopaminergic (DA) neurons. Overexpression of these LRRK2 proteins causes age-dependent DA neurodegeneration, behavioral deficits, and locomotor dysfunction that are accompanied by a reduction of dopamine levels in vivo. In comparison, R1441C and G2019S mutants cause more severe phenotypes than the wild type protein. Interestingly, treatment with exogenous dopamine rescues the LRRK2-induced behavioral and locomotor phenotypes. In contrast, expression of the GTP binding defective mutant, K1347A, or knockout of the C. elegans LRRK2 homolog, LRK-1, prevents the LRRK2-induced neurodegeneration and behavioral abnormalities. Hence, our transgenic LRRK2 C. elegans models recapitulate key features of PD including progressive neurodegeneration, impairment of dopamine-dependent behavior and locomotor function, and reduction in dopamine levels. Furthermore, our findings provide strong support for the critical role of GTPase/kinase activity in LRRK2-linked pathologies. These invertebrate models will be useful for studying pathogenesis of PD and for development of potential therapeutics for the disease.
Introduction
Parkinson's disease (PD) is a common neurodegenerative disorder characterized clinically by tremor, rigidity, bradykinesia, and postural instability, and pathologically by selective loss of dopaminergic (DA) neurons in affected brain regions. Mutations in leucine-rich repeat kinase 2 (LRRK2) represent the most frequent cause of autosomal dominant and idiopathic PD identified to date (Paisan-Ruiz et al., 2004; Zimprich et al., 2004) . LRRK2 is a large multi-domain protein with both a GTPase and a kinase domain within the same molecule (Cookson et al., 2007; Gandhi et al., 2009; Guo et al., 2006; Mata et al., 2006) . About 30 LRRK2 sequence variations have been identified (Brice, 2005; Farrer et al., 2005; Farrer, 2007; Nichols et al., 2007; Zabetian et al., 2005; Zimprich et al., 2004) . Among them, the R1441C/G mutation within the GTPase domain, and the G2019S mutation within the kinase domain of LRRK2 occur more frequently and have been definitively linked to PD, highlighting an unprecedented role of GTPase and kinase signaling in the pathogenesis of the disease.
The normal function of LRKK2 or its closely related LRRK1 is not well understood. Null alleles of lrk-1 that encodes the sole LRRK2 homolog (LRK-1) in Caenorhabditis elegans (C. elegans) exhibit some defects in polarized sorting of synaptic vesicles (Sakaguchi-Nakashima et al., 2007) . Knockdown of LRRK2 has been shown to promote neurite outgrowth, while overexpressing mutant LRRK2 has an opposing effect (MacLeod et al., 2006) . However, it is unknown whether loss-of-function in LRK-1 and LRRK2 affects survival of DA neurons. Recent in vitro studies have suggested a possible gain-offunction mechanism for some PD-linked mutations. Biochemical investigations have shown that LRRK2 mutations such as R1441C and G2019S mutations lead to an increase in kinase activity of LRRK2 when overexpressed in cultured cells (Gloeckner et al., 2006; West et Neurobiology of Disease 40 (2010) 73-81 
